Analysis of the Serum Peptidomics Profile for Cats With Sarcomeric Gene Mutation and Hypertrophic Cardiomyopathy

Pratch Sukumolanan¹, Narumon Phanakrop², Siriwan Thaisakun³, Sittiruk Roytrakul³ and Soontaree Petchdee⁴*

¹ Veterinary Clinical Studies Program, Faculty of Veterinary Medicine, Graduated School, Kasetsart University, Nakorn Pathom, Thailand, ² Functional Ingredients and Food Innovation Research Group, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani, Thailand, ³ Proteomics Research Laboratory, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani, Thailand, ⁴ Department of Large Animal and Wildlife Clinical Sciences, Faculty of Veterinary Medicine, Kasetsart University, Nakorn Pathom, Thailand

Background: Hypertrophic cardiomyopathy (HCM) has a complex phenotype that is partly explained by genetic variants related to this disease. The serum peptidome profile is a promising approach to define clinically relevant biomarkers. This study aimed to classify peptide patterns in serum samples between cats with sarcomeric gene mutations and normal cats.

Materials and Methods: In the total serum samples from 31 cats, several essential proteins were identified by peptidomics analysis. The 5,946 peptides were differentially expressed in cats with sarcomeric gene mutations compared with cats without mutations.

Results: Our results demonstrated characteristic protein expression in control cats, Maine Coon cats, and Maine Coon cats with gene mutations. In cats with gene mutations, peptide expression profiling showed an association with three peptides, Cytochrome 3a132 (CYP3A132), forkhead box O1 (FOXO1), and ArfGAP, with GTPase domains, ankyrin repeats, and PH domain 2 (AGAP2).

Discussion: The serum peptidome of cats with mutations might provide supporting evidence for the dysregulation of metabolic and structural proteins. Genetic and peptidomics investigations may help elucidate the phenotypic variability of HCM and treatment targets to reduce morbidity and mortality of HCM in cats.

Keywords: feline, hypertrophic cardiomyopathy, myocardial disease, peptidomics analysis, echocardiography

INTRODUCTION

Myocardial disease is the most common genetic heart problem in cats, especially in Maine Coon, Ragdoll, and Persian cats. Hypertrophic cardiomyopathy (HCM) is one of the most common genetic heart problems in cats. HCM is a myocardial disease caused by dominant mutations in genes encoding cardiac sarcomere protein. Many gene polymorphisms, such as MYBPC3-A31P
and A74T, have been detected in Maine Coon cats or cats crossbred with Maine Coon cats (1–4). HCM can be characterized by an increase in left ventricular myocardial mass. However, other causes of cardiac hypertrophy, such as hyperthyroidism, systemic hypertension, and aortic stenosis, are the primary differential diagnosis for this disease (5–7).

The complex and dynamic pathophysiological mechanisms surrounding cardiac hypertrophy have focused on many investigations seeking therapeutic strategies (8). Additional studies may involve understanding the risk factors for cardiovascular disease. Many studies have investigated the pathway that plays critical roles in mediating cardiac hypertrophy (9–12). The mechanisms for the effect of testosterone on muscle hypertrophy are not entirely understood. It is known that free testosterone concentrations increase in response to cardiac muscle hypertrophy (13). Previous studies have suggested that testosterone-induced cardiomyocyte hypertrophy is accompanied by increased glucose uptake and glycolysis. In addition, testosterone increased AMPK phosphorylation, which is the crucial pathway in the development of eccentric hypertrophy (14).

Peptide analysis is being increasingly used to identify the protein changes accompanying changes in clinical appearance. Two-dimensional gel electrophoresis coupled with mass spectrometry offers a key advantage of profiling proteins in biological samples. Alterations in the proteome profile determined using two-dimensional gel electrophoresis in conjunction with matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry may explain the mechanistic pathways and identify novel potential biomarkers for the diagnosis and prognosis of HCM in cats. The proteomic data may contribute to understanding the pathogenesis of myocardial remodeling, and the proteins found may be candidate biomarkers for the diagnosis and prognosis of HCM in cats.

The purpose of this study is to provide important information on clinical presentation, protein expression, and genes associated with feline HCM. The detection of HCM with a normal phenotype in the early stage may provide an advantage for the treatment strategies, prognosis, and prevention of HCM in the clinic.

MATERIALS AND METHODS

Animals

This study design is a case-control study. The study protocol was approved by the Ethics Committee, Kasetsart University (ACKU-62-VE-059), and written informed consent from the owners. Thirty-one cats, 17 domestic shorthair cats, and 14 Maine Coon cats were enrolled in this study. The cat underwent a complete physical examination to evaluate the general condition. A complete blood count and serum biochemistry profile were performed for each cat. The cardiovascular system is evaluated by echocardiographic analysis. B-mode and M-mode echocardiography were used to define the left ventricular structure. The thickening of left ventricular wall at diastole phase which more than 6 mm indicated left ventricular hypertrophy (15). Echocardiography images have demonstrated left ventricular hypertrophy, the dynamic obstruction of the left ventricular outflow tract, which are common findings in HCM cats, as shown in Figure 1.

DNA Sequencing

DNA amplification was performed to detect MYBPC3-A31P and A74T. The PCR product was extracted and purified with FavorPrep GEL/PCR Purification Kit, Taiwan. The purified PCR product was stored at −20°C. The Sanger sequencing method was performed to detect the PCR product's nucleotide with a specific forward and reverse primer. MYBPC3-A31P and A74T polymorphism was detected using Bioedit program and ApE (A plasmid Editor) program.

Analysis of Peptide Patterns by MALDI-TOF MS

The protein concentration in serum was determined by the Lowry method (16). The absorbance at 750 nm (OD750) was measured, and the protein concentration was calculated using the standard curve, plotted between OD750 on Y-axis and BSA concentration (g/ml) on X-axis. The peptides from serum were acidified with 0.1% trifluoroacetic acid to the final concentration of 0.1 mg/ml. The peptides were mixed with MALDI matrix solution (10 mg sinapinic acid in 1 ml of 50% acetonitrile containing 0.1% trifluoroacetic acid), directly spotted onto MALDI target (MTP 384 ground steel, Bruker Daltonik, GmbH), and allowed to dry at room temperature. Maldi-TOF MS spectra were collected using Ultraflex III TOF/TOF (Bruker Daltonik, GmbH) in a positive linear mode with a mass range of 2,000–15,000 Da. Five hundred shots were accumulated with a 50 Hz laser for each sample. MS spectra were analyzed by using flexAnalysis and ClinproTool software (Bruker Daltonik, GmbH), including fingerprint spectra, pseudo-gel view, and principal component analysis (PCA). ACTH fragment 18–39 (human), Insulin oxidized B chain (bovine), Insulin (bovine), Cytochrome C (equine), and Apomyoglobin (equine) were used as external protein calibrations.

Peptidomics Analysis by LC-MS

Peptide solutions were analyzed using an HCTultra PTM Discovery System (Bruker Daltonics Ltd., Germany.) coupled to an UltiMate 3000 LC System (Dionex Ltd., U.K.). Peptides were separated on a nanocolumn (PepSwift monolithic column 100 μ m i.d. × 50 mm). Eluent A was 0.1% formic acid, and eluent B was 80% acetonitrile in water containing 0.1% formic acid. Peptide separation was achieved with a linear gradient from 10 to 70% B for 13 min at a flow rate of 300 nL/min, including a regeneration step at 90% B and an equilibration step at 10% B. One run took 20 min. Peptide fragment mass spectra were acquired in data-dependent AutoMS (2) mode with a scan range of 300–1,500 m/z, three averages, and up to 5 precursor ions selected from the MS scan 50–3,000 m/z.

For peptides quantitation, DeCyder MS Differential Analysis software (DeCyderMS, GE Healthcare) was used (17, 18). Acquired LC-MS raw data were converted, and the PepDetect module was used for automated peptide detection, charge
state assignments, and quantitation based on the peptide ions signal intensities in MS mode. The analyzed MS/MS data from DeCyderMS were submitted for a database search using the Mascot software (Matrix Science, London, UK) (19). The data were searched against the NCBI database for protein identification. Database interrogation was: taxonomy (Canis lupus familiaris); enzyme (trypsin); variable modifications (carbamidomethyl, oxidation of methionine residues); mass values (monoisotopic); protein mass (unrestricted); peptide mass tolerance (1.2 Da); fragment mass tolerance (± 0.6 Da); peptide charge state (1+, 2+, and 3+) and max missed cleavages. The maximum value of each group was used to determine the presence or absence of each identified protein.

Data normalization and quantification of the changes in peptide abundance between the control and Maine Coon cats were performed and visualized using MultiExperiment Viewer (MeV) software version 4.6.1 (20). Briefly, peptide intensities from the LC-MS analyses were transformed and normalized using a mean central tendency procedure.

Statistical Analysis

Data are presented as mean ± standard error of the mean (SEM). The normal distribution of data sets were conducted and then analyzed using one-way analysis of variance (ANOVA), a P < 0.05 was considered statistically significant.

RESULTS

Cats in the control group had the higher trend of age than the Maine Coon group (5.01 vs. 1.97 years, P = 0.065). In addition, there were significant differences by sex and weight between cats in the control and Maine Coon group. General characteristics and echocardiographic parameters for all cats are reported in Table 1. Blood profiles and serum biochemistry are reported in Table 2. Serum biochemistry (BUN/creatinine ratio) showed a statistically significant increase in control groups than cats in the Maine Coon group (P = 0.032). However, the levels of other biochemical profiles such as creatinine and blood urea nitrogen were not significantly different between groups. In addition, the blood profiles such as red blood cell count and hematocrit are not different in the control group vs. the Maine Coon group.

Analysis of the association between Maine Coon cats and genotype at A31P and A74T mutation was performed. Results showed significant differences between 78.57% (n = 11) and 21.43% (n = 3) genotypes for the homozygous wildtype and heterozygous mutation, respectively (Figure 2).

Three-dimension component analysis showed distinct clusters among the sarcomeric gene mutation, non-mutation cats, and
normal control groups. All 31 replicates from each pooled serum sample group exhibited a distinguished cluster from the others, indicating a distinctive peptide profile in each group and demonstrating the uniformity and homogeneity of data within the groups as showed in Figure 3. In the present study, peptidomics analysis showed a total of 5,946 peptides differentially expressed between groups (Figure 4). STITCH version 5.0 was used to determine the protein names and interactions. Results showed that eight peptides were found to be up-regulated in the Maine Coon group including, IQ motif and Sec7 domain 2 (IQSEC2), zinc finger NFX1-type containing 1 (ZNFX1), discs large (Drosophila) homolog-associated protein 1 (DLGAP1), CTS telomere maintenance complex component 1 (CTC1), opiate receptor-like 1 (OPRL1), aryl hydrocarbon receptor nuclear translocator-like (ARNTL), nudix (nucleoside diphosphate linked moiety X)-type motif 16 (NUDT16), and KH domain containing RNA binding signal transduction associated 2 (KHDRBS2). In addition, three peptides were up-regulated in the Maine Coon group with sarcomeric gene mutation containing, cytochrome 3a132 (CYP3A132), forkhead box O1 (FOXO1), and ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 (AGAP2).

The proteins were identified using Gene Ontology Annotation Database. The expression of hepatic markers such as CYP3a132 was investigated in the present study, CYP3a132 has been reported to associate with liver disease in domestic cats (21). In addition, gene mutation cats were associated with specific antioxidant defense changes in a distinct functional group of proteins. The different expression peptides were from a wide range of functional classes and included proteins involved in signal transduction, such as FOXO1. Transcription factor FOXO1 plays an essential role in glucose metabolism, cell cycle progression, apoptosis, and differentiation (22).

Moreover, AGAP2 was another peptide that expressed in the gene mutation Maine Coon cats. AGAP2 seems to be involved in TGFβ1 signaling that could contribute to the progression of hepatic fibrosis, suggesting AGAP2 as a potential new molecular target for liver fibrogenesis (23). Moreover, the peptides of gene mutation in cats were associated with testosterone, analgesic, anticonvulsant, and anticancer drugs, as shown in Figure 4.

Verification of expressed protein sequences by LC-MS, the peptides mass peaks were compared among groups (Figure 5).

**DISCUSSION**

In this study, the differential peptidomic profiles expressed in Maine Coon cats compared to control cats may provide complementary tools for detecting and evaluating hypertrophic cardiomyopathy. Results showed the protein and drug interaction networks of proteins that dominate in sarcomeric gene mutation cats (Figure 4B). Since diseases are often a consequence of multiple changes in the same pathway or protein...
FIGURE 3 | Principal component analysis shows Maine Coon cats samples segregate from control cats. A three-dimensional scatterplot plot of non-gene mutation, gene mutation (A31P and A74T), and left ventricular wall hypertrophy cats (LV wall Thickening).

FIGURE 4 | (A) The diagram represents overlap among protein types with 5,946 identified proteins. (B) Protein and drug interaction networks of proteins dominate in sarcomeric gene mutation cats.

complex, the role of proteins in biological systems can be understood with the function of the targeted small molecules or drugs. Chemicals or drugs in the interaction network predicted by STITCH can lead to a better understanding of the potential function of the interacting protein partners. Among the expressed peptides, three peptides were increased in Maine Coon
cats with sarcomeric gene mutations compared to nonmutated cats. The findings in our study are consistent with previously reported findings that the proteins involved in glucogenesis and oxidative phosphorylation are closely related to cardiac hypertrophy. The proteins identified in the cat with sarcomeric gene mutations included FOXO1 and CYP3A132. These proteins have an important role in several conditions associated with testosterone and glucose metabolic control. Testosterone has been reported to stimulate glucose metabolism by activating AMP-activated protein kinase (AMPK) and androgen receptor (AR) signaling, which are critical for induction of cardiomyocyte hypertrophy. Our results suggest that inhibiting AMPK and AR may help block glycolysis and cardiomyocyte hypertrophy, similar to the findings in previous reports (14). However, further studies should be performed to confirm this result.

FOXO1 is a transcription factor that modulates cell apoptosis and cell differentiation (24). It has been reported that TGFβ1 regulates the overexpression of FOXO1 as a consequence of inducing cardiac myoblast differentiation to myofibroblasts (25). Thus, FOXO1 may be related to the pathway of cardiac fibrosis and cardiac hypertrophy in Maine Coon cats with sarcomeric protein mutations. Similar to the findings in chronic intermittent hypoxia, FOXO1 induces upregulated expression of an apoptosis-related gene (Bim) and caspase 9, leading to cardiac hypertrophy in obstructive sleep apnea syndrome (26). Furthermore, this finding agrees with previous research showing that the regulation of FOXO1 is correlated with apoptosis-related genes such as Bel-2 and Bim (27). A report in 2020 revealed that FOXO1 knockdown or deletion reduces cardiac hypertrophy caused by pressure overload (28).

AGAP2 is a GTPase-activating protein associated with numerous signaling pathways, including cell survival, cellular migration, and cell apoptosis. Evidence has shown that AGAP2 regulates profibrotic properties in liver fibrosis via TGFβ1. In addition, elevated AGAP2 acts as a pathological factor of cancer and liver fibrosis (29). According to the results in this study, AGAP2 might be correlated with cardiac fibrosis and hypertrophy in Maine Coon cats with HCM. However, reports linking AGAP2 with cardiac hypertrophy in cats still require further confirmation.

CYP3A132 belongs to the cytochrome P450 3A (CYP3A) family and is normally expressed in the liver (21). A previous study reported that CYP3A132 could be used as a marker for liver fibrosis. CYP3A132 has been found in domestic cats and is related to biotransformation and therapeutic drug metabolism, including that of calcium channel blockers, benzodiazepines, and immunosuppressant drugs (21). Moreover, subclinical liver fibrosis is associated with a history of atrial fibrillation, heart failure, and congestive heart disease (30). CYP3A132 was expressed in Maine Coon cats with sarcomeric gene mutations compared with nonmutated cats. Therefore, CYP3A132 may be used as a marker to detect cardiac hypertrophy in cats. However, further studies are warranted to determine the relationship between these peptides and HCM in cats.

According to the crucial serum biochemistry, thyroxine hormone concentration and feline NT-proBNP plasma concentration should use as a screening tool for cats with subclinical hypertrophic cardiomyopathy (HCM). These factors can influence the inclusion criteria in our study. Unfortunately, in this study, these factors were not measured, which is our study's limitation. However, our study used transthoracic echocardiography to measure left ventricular wall thickness is considered the reliable criteria in classifying HCM as recommended in the ACVIM guidelines (31).

CONCLUSION

The MYBPC3-A31P and A74T mutations had a high frequency in Maine Coon cats. A mutation was associated with the
hypertrophic cardiomyopathy phenotype. Peptidomic testing of Maine Coon cats will be a helpful tool for identifying carriers of the mutated gene for myocardial disease in cats. The results from this study may provide important information on clinical presentation, protein expression, and a gene associated with feline HCM.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary materials, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The animal study was reviewed and approved by the Animal Care Committee of Kasetsart University, Approval Number ACKU-62-VET-059. Written informed consent was obtained from the owners for the participation of their animals in this study.

REFERENCES

1. Fries R, Haney AM, Meurs KM. Prevalence of the myosin-binding protein C mutation in Maine Coon cats. J Vet Intern Med. (2008) 22:893–6. doi: 10.1111/j.1939-1676.2008.0113.x
2. Mary J, Chebbou V, Sampedrano CC, Abtibol M, Gouni V, Trehiou-Sechi E, et al. Prevalence of the MYBPC3-A31P mutation in a large European feline population and association with hypertrophic cardiomyopathy in the Maine Coon breed. J Vet Cardiol. (2010) 12:155–61. doi: 10.1016/j.jvc.2010.06.004
3. Wess G, Schinner C, Weber K, Küchenhoff H, Hartmann K. Association of A31P and A74T polymorphisms in the myosin binding protein C3 gene and hypertrophic cardiomyopathy in Maine Coon and other breed cats. J Vet Intern Med. (2010) 24:527–32. doi: 10.1111/j.1939-1676.2010.0151.x
4. Longeri M, Ferrari P, Knafel P, Mezzelani A, Marabotti A, Máñeses L, et al. Myosin-binding protein C DNA variants in domestic cats (A31P, A74T, R820W) and their association with hypertrophic cardiomyopathy. J Vet Intern Med. (2013) 27:275–85. doi: 10.1111/jvim.12031
5. Häggström J, Fuentes VL, Wess G. Screening for hypertrophic cardiomyopathy in cats. J Vet Cardiol. (2015) 17:5134–S49. doi: 10.1016/j.jvc.2015.07.003
6. Kitamura Y, Mise N, Mori Y, Suzuki Y, Ohashi T, Tada-Oikawa S, et al. Proteomic identification of the proteins related to cigarette smoke-induced cardiac hypertrophy in spontaneously hypertensive rats. Sci Rep. (2020) 10:1–12. doi: 10.1038/s41598-020-0224-3
7. Said S, Hernandez GT. The link between chronic kidney disease and cardiovascular disease. J Nephrol. (2014) 3:99–104. doi: 10.12860/njp.2014.19
8. Wang J, Choi H, Chung NC, Cao Q, Ng DCM, Mirza B, et al. Integrated dissection of cysteine oxidative post-translational modification proteome during cardiac hypertrophy. J Proteome Res. (2018) 17:4243–57. doi: 10.1021/acs.jproteome.8b00372
9. Lau E, Cao Q, Lam MFP, Wang J, Ng DCM, Bleakley BJ, et al. Integrated omics dissection of proteome dynamics during cardiac remodeling. Nat Commun. (2018) 9:1–14. doi: 10.1038/s41467-017-0246-3
10. Gomes AV, Kazmierczak K, Cheah JX, Gilda JE, Yuan CC, Zhou Z, et al. Proteomic analysis of physiological versus pathological cardiac remodeling in animal models expressing mutations in myosin essential light chains. J Muscle Res Cell Motil. (2015) 36:447–61. doi: 10.1007/s10974-015-9434-0
11. Li Z, Liu N, Zhang LS, Gong K, Cai Y, Gao W, et al. Proteomic profiling reveals comprehensive insights into adrenergic receptor-mediated hypertrophy in neonatal rat cardiomyocytes. Proteomics Clin Appl. (2009) 3:1407–21. doi: 10.1002/prca.200900029
12. Troncoso MF, Pavez M, Wilson C, Lagos D, Duran J, Ramos S, et al. Testosterone activates glucose metabolism through AMPK and androgen signaling in cardiomyocyte hypertrophy. Biol Res. (2021) 54:1–16. doi: 10.1186/s40659-021-00328-4
13. Kraemer RR, Hollander DB, Reeves GV, Francois M, Ramadan ZG, Meeker B, et al. Similar hormonal responses to concentric and eccentric muscle actions using relative loading. Eur J Appl Physiol. (2006) 96:551–7. doi: 10.1007/s00424-005-0094-4
14. Zhang W, Elimbam V, Nijjar GS, Gupta SK, Dhalla NS. Role of mitogen-activated protein kinase in cardiac hypertrophy and heart failure. Exp Clin Cardiol. (2003) 8:173–83.
15. Fox PK, Liu SK, Maron BJ. Echocardiographic assessment of spontaneously occurring feline hypertrophic cardiomyopathy: an animal model of human disease. Circulation. (1995) 92:2645–51. doi: 10.1161/01.CIR.9 2.9.2645
16. Lowry OH, Rosebrown NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. (1951) 193:265–75. doi: 10.1016/S0021-9258(19)52451-6
17. Johansson C, Samskog J, Sundström L, Wadensten H, Björksten L, Flensburg J. Differential expression analysis of Escherichia coli proteins using a novel software for relative quantitation of LC-MS/MS data. Proteomics. (2006) 6:4475–85. doi: 10.1002/pmc.200500921
18. Thorsell A, Portelius E, Blennow K, Westman-Brinkmalm A. Evaluation of sample fractionation using micro-scale liquid-phase isoelectric focusing on mass spectrometric identification and quantification of proteins in a SILAC experiment. Rapid Commun Mass Spectrom. (2007) 21:771–8. doi: 10.1002/rcm.2898
19. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. (1999) 20:3551–67. doi: 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2
20. Howe E, Holton K, Nair S, Schlauch D, Sinha R, Quackenbush J. MElV: Multiexperiment viewer. In: Ochs M, Casagrande J, Davuluri R, editors. Biomedical Informatics for Cancer Research. Boston, MAL Springer (2010). p. 267–77.
21. Honda K, Komatsu T, Koyama F, Kubota A, Kawakami K, Asakura H, Li Z, Liu N, Zhang LS, Gong K, Cai Y, Gao W, et al. Proteomic profiling reveals comprehensive insights into adrenergic receptor-mediated hypertrophy in neonatal rat cardiomyocytes. Proteomics Clin Appl. (2009) 3:1407–21. doi: 10.1002/prca.200900029
22. Xing YQ, Li A, Yang Y, Li XX, Zhang LN, Guo HC. The regulation of FOXO1 and its role in disease progression. Life Sci. (2018) 193:124–31. doi: 10.1016/j.lfs.2017.11.030

AUTHOR CONTRIBUTIONS

SP and PS wrote the original manuscript and prepared figures. SR, ST, NP, and SP analyzed and interpreted the data regarding the serum peptidomics profiles. PS performed the PCR and DNA sequencing. SP was a major contributor in writing the manuscript. All authors read and approved the final version of the manuscript.

FUNDING

This research project was supported by National Research Council of Thailand (NRCT): NRCT5-RGJ63002-035.

ACKNOWLEDGMENTS

The authors are grateful to Kasetsart University Veterinary Teaching Hospital, Faculty of Veterinary Medicine, Kasetsart University, for providing facilities for the study.
23. Navarro-Corcuera A, López-Zabalza MJ, Martínez-Irujo JJ, Álvarez-Sola G, Ávila MA, Iribaruj MJ, et al. Role of AGAP2 in the profibrogenic effects induced by TGFβ in LX-2 hepatic stellate cells. *Biochim Biophys Acta Mol Cell Res.* (2019) 1866:673–85. doi: 10.1016/j.bbamcr.2019.01.008

24. Ronnebaum SM, Patterson C. The FoxO family in cardiac function and dysfunction. *Annu. Rev. Physiol.* (2010) 72:81–94. doi: 10.1146/annurev-physiol-021909-135931

25. Vivar R, Humeres C, Muñoz C, Boza P, Bolivar S, Tapia F, et al. FoxO1 mediates TGF-beta1-dependent cardiac myofibroblast differentiation. *Biophys Acta Mol Cell Res.* (2016) 1863:128–38. doi: 10.1016/j.bbamcr.2015.10.019

26. Li G, Jin M, He Y, Ren J, Zhang M, Chen Y, et al. Fork head box class o1 (foxo1) activates BIM expression to mediate cardiac apoptosis in chronic intermittent hypoxia-induced cardiac hypertrophy. *Med Sci Mon Int Med J Exp Clin Res.* (2017) 23:3603. doi: 10.12659/MSM.905210

27. Yu W, Chen C, Cheng J. The role and molecular mechanism of FoxO1 in mediating cardiac hypertrophy. *ESC Heart Fail.* (2020) 7:3497–504. doi: 10.1002/ehf2.13065

28. Pfleger J, Coleman RC, Ibetti J, Roy R, Kyriazis ID, Gao E, et al. Genomic binding patterns of forkhead box protein o1 reveal its unique role in cardiac hypertrophy. *Circulation.* (2020) 142:882–98. doi: 10.1161/CIRCULATIONAHA.120.046356

29. Navarro-Corcuera A, Ansorena E, Montiel-Duarte C, Iriburu MJ. AGAP2: modulating TGFβ1-signaling in the regulation of liver fibrosis. *Int J Mol Sci.* (2020) 21:1400. doi: 10.3390/ijms21041400

30. Ostovaneh MR, Ambale-Venkatesh B, Fuji T, Bakhshi H, Shah R, Murthy VL, et al. Association of liver fibrosis with cardiovascular diseases in the general population: the multi-ethnic study of atherosclerosis (MESA). *Circ Cardiovasc Imaging.* (2018) 11:e007241. doi: 10.1161/CIRCIMAGING.117.007241

31. Fuentes VL, Abbott J, Chetboul V, Côté E, Fox PR, Häggström J, et al. ACCVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats. *J Vet Intern Med.* (2020) 34:1062–77. doi: 10.1111/jvim.15745

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2021 Sukumolanan, Phanakrop, Thaisakun, Roytrakul and Petchdee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*